Reversible renal insufficiency attributable to thyroid hormone withdrawal in a patient with type 2 diabetes mellitus

Endocrine Practice

Volumn 10, Issue 4, 2004, Pages 339-344

  Bernet, Victor J ^a,b  

^a Walter Reed Army Medical Center ^*

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIAGNOSTIC AGENT; METFORMIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROID HORMONE;

ADENOCARCINOMA; ARTICLE; CASE REPORT; HUMAN; KIDNEY FAILURE; MALE; METHODOLOGY; MIDDLE AGED; NECK DISSECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOISOTOPE DIAGNOSIS; SCINTISCANNING; THYROID FUNCTION TEST; THYROID TUMOR; THYROIDECTOMY; TREATMENT WITHDRAWAL;

ADENOCARCINOMA, PAPILLARY; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; HUMANS; HYPOGLYCEMIC AGENTS; IODINE RADIOISOTOPES; KIDNEY FAILURE; MALE; METFORMIN; MIDDLE AGED; NECK DISSECTION; RADIOPHARMACEUTICALS; THYROID FUNCTION TESTS; THYROID HORMONES; THYROID NEOPLASMS; THYROIDECTOMY; WITHHOLDING TREATMENT;

EID: 17144393755     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.4.339     Document Type: Article

References (36)

1. Polednak AP. Trends in cancer incidence in Connecticut, 1935-1991. Cancer. 1994;74:2863-2872.
2. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936-1940.
3. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25-33.
4. Maxon HR. Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid. 1999;9:443-446.
5. Torrens JI, Burch HB. Serum thyroglobulin measurement: utility in clinical practice. Endocrinol Metab Clin North Am. 2001;30:429-467.
6. Schimmel M, Utiger RD. Thyroidal and peripheral production of thyroid hormones: review of recent findings and their clinical implications. Ann Intern Med. 1977;87:760-768.
7. Shapiro LE, Surks MI. Hypothyroidism. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001: 445-454.
8. Derubertis FR Jr, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. Am J Med. 1971;51:41-53.
9. Tajiri J, Shimada T, Naomi S, Umeda T, Sato T. Hepatic dysfunction in primary hypothyroidism. Endocr J. 1984;31:83-91.
10. Azizi F. Gamma-glutamyl transpeptidase levels in thyroid disease. Arch Intern Med. 1982;142:79-81.
11. Ekbom K, Hed R, Herdenstam CG, Nygren A. The serum creatine phosphokinase activity and the Achilles reflex in hyperthyroidism and hypothyroidism. Acta Med Scand. 1966;179:433-440.
12. Gow SM, Caldwell G, Toft AD, Beckett GJ. Different hepatic responses to thyroxine replacement in spontaneous and 131I-induced primary hypothyroidism. Clin Endocrinol (Oxf). 1989;30:505-512.
13. Katz AI, Emmanouel DS, Lindheimer MD. Thyroid hormone and the kidney. Nephron. 1975;15:223-249.
14. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159:79-82.
15. Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis. 1996;27:195-198.
16. Reza MJ, Abbasi AS. Congestive cardiomyopathy in hypothyroidism. West J Med. 1975;123:228-230.
17. Brown SD, Barsher RE, Schnute RB. Pleural effusion in a young woman with myxedema. Arch Intern Med. 1983;143:1458-1460.
18. Burgerman A. Myxedema with pericardial effusion. Med Ann Dist Columbia. 1966;35:126-133 passim.
19. Davis PJ, Jacobson S. Myxedema with cardiac tamponade and pericardial effusion of "gold paint" appearance. Arch Intern Med. 1967;120:615-619.
20. Ogata S, Yorioka N, Tanji C, et al. Two cases of hypothyroidism complicated by renal dysfunction. Hiroshima J Med Sci. 2000;49:93-96.
21. Metformin for non-insulin-dependent diabetes mellitus. Med Lett Drugs Ther. 1995;37:41-42.
22. Villabona C, Sahun M, Roca M, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci. 1999;318:277-280.
23. Nakahama H, Sakaguchi K, Horita Y, Nakamura S, Inenaga T, Takishita S. Treatment of severe hypothyroidism reduced serum creatinine levels in two chronic renal failure patients. Nephron. 2001;88:264-267.
24. Bald M, Hauffa BP, Wingen AM. Hypothyroidism mimicking chronic renal failure in reflux nephropathy. Arch Dis Child. 2000;83:251-252.
25. Makino Y, Fujii T, Kuroda S, Inenaga T, Kawano Y, Takishita S. Exacerbation of renal failure due to hypothyroidism in a patient with ischemic nephropathy. Nephron. 2000;84:267-269.
26. Mooraki A, Bastani B. Reversible renal insufficiency, hyperuricemia and gouty arthritis in a case of hypothyroidism. Clin Nephrol. 1998;49:59-61.
27. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with endstage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab. 2000;85: 3058-3064.
28. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371-1377.
29. Park SG, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism [abstract]. J Nucl Med. 1996; 37(Suppl):5P.
30. Misbin RI. Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med. 1977;87:591-595.
31. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22:925-927.
32. Franklyn JA. Metabolic changes in hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid. 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2000: 833-837.
33. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [erratum in Diabetes Care. 2003;26:972]. Diabetes Care. 2003;26 (Suppl 1):S33-S50.
34. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
35. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
36. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9:227-247.